(Q44064648)

29 November 2017

title

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation (English)

1 reference

29 November 2017

1 reference

Nasimul Ahsan

1

1 reference

29 November 2017

Michael J Holman

2

1 reference

29 November 2017

Mark V Jarowenko

3

1 reference

29 November 2017

Mohammad S Razzaque

4

1 reference

29 November 2017

Harold C Yang

5

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

American Journal of Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

2

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

568-573

1 reference

One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

The Banff 97 working classification of renal allograft pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Interleukin 2 receptor-targeted therapy--rationale and applications in organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2002.20612.X

7 January 2021

10.1034/J.1600-6143.2002.20612.X

Identifiers

DOI

1 reference

29 November 2017

1 reference